A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

PHASE3CompletedINTERVENTIONAL

Enrollment

468

Participants

Timeline

Start Date

December 2, 2013

Primary Completion Date

September 28, 2016

Study Completion Date

September 28, 2016

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Ertugliflozin 5 mg

Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks

DRUG

Placebo 5 mg

Placebo to ertugliflozin, oral, tablet, 5 mg tablet once daily for 52 weeks

DRUG

Ertugliflozin 10 mg

Ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks

DRUG

Placebo 10 mg

Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks